Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.

Background Malignant pleural mesothelioma (MPM) continues to be a distressing tumor due to its aggressive biologic behavior and scanty prognosis. Several therapeutic approaches have been tested both in clinical and preclinical settings, being intrapleural chemotherapy one of the most promising. Some years ago, our interest focused on polymeric films loaded with cisplatin for the adjuvant intrapleural treatment of surgical patients. After in vitro and in vivo studies in a rat recurrence model of MPM, the aim of this study was to evaluate the pharmacokinetics of the polymeric films in a sheep model in view of further studies in a clinical setting. Methods An ovine model was used. Animals were divided into four groups according to pharmacologic treatment: control group (three animals undergoing left pneumonectomy and saline-NaCl solution); intrapleural hyaluronate cisplatin films (HYALCIS) group (six animals undergoing left pneumonectomy and intrapleural application of polymeric films loaded with cisplatin); intrapleural cisplatin solution (six animals undergoing left pneumonectomy and intrapleural application of cisplatin solution); intravenous cisplatin (five animals undergoing left pneumonectomy and intravenous administration of cisplatin solution). The primary objective was the plasmatic and pleural concentration of cisplatin in the treatment groups. The secondary objective was the treatment-related toxicity evaluated by plasmatic analysis performed at prearranged time intervals and histological examinations of tissue samples collected during animal autopsy. Analysis of variance (ANOVA) was used for statistical analysis. Bonferroni correction was applied for comparison between all groups. Results Twenty female Sardinian sheep with a mean weight of 45.1 kg were studied. All animals survived the surgical procedures. The whole surgical procedure had a mean duration of 113 minutes. Cisplatin blood levels obtained from polymeric films application were low during the first 24 hours after the application; then, the cisplatin blood level increased gradually and progressively until it reached significantly higher plasmatic concentrations after 120 hours compared to intrapleural cisplatin solution (P=0.004) and intravenous administration (P=0.001), respectively. Considering cisplatin concentration at 168 hours after the application, animals treated with polymeric films had higher plasmatic values than animals treated with intrapleural cisplatin solution and intravenous cisplatin (P=0.001). Despite the high cisplatin plasmatic concentrations, treatment related-toxicity towards kidneys and liver was comparatively lower compared to the intravenous and intrapleural cisplatin administration and closer to the control levels. Conclusions Polymeric films loaded with cisplatin allowed to reach significantly higher intrapleural and plasmatic cisplatin concentrations compared to intrapleural and intravenous cisplatin solution, providing at the same time, a significant reduction of treatment related toxicity.

[1]  F. Petrella,et al.  Malignant Pleural Mesothelioma: State of the art and advanced cell therapy. , 2017, European journal of medicinal chemistry.

[2]  M. Tiseo,et al.  MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study , 2017, Disease markers.

[3]  K. Aigner,et al.  Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma , 2017, OncoTargets and therapy.

[4]  D. Sugarbaker,et al.  Intraoperative adjuncts for malignant pleural mesothelioma. , 2017, Translational lung cancer research.

[5]  M. de Perrot,et al.  Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma. , 2017, Translational lung cancer research.

[6]  B. Świątkowska,et al.  Mesothelioma continues to increase even 40 years after exposure - Evidence from long-term epidemiological observation. , 2017, Lung cancer.

[7]  P. Adusumilli,et al.  Immunotherapy for malignant pleural mesothelioma: current status and future directions. , 2017, Translational lung cancer research.

[8]  K. Okabe Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma. , 2017, Annals of translational medicine.

[9]  D. Sugarbaker,et al.  Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient. , 2017, Journal of thoracic disease.

[10]  S. Hasegawa,et al.  Pleurectomy/decortication for malignant pleural mesothelioma. , 2017, Journal of thoracic disease.

[11]  T. Ishida,et al.  Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma. , 2015, Biological & pharmaceutical bulletin.

[12]  O. Ogunseitan The asbestos paradox: global gaps in the translational science of disease prevention , 2015, Bulletin of the World Health Organization.

[13]  I. Opitz Management of malignant pleural mesothelioma-The European experience. , 2014, Journal of thoracic disease.

[14]  Victoria Keena,et al.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. , 2013, Journal of thoracic disease.

[15]  N. van Zandwijk,et al.  Clinical practice guidelines for malignant pleural mesothelioma. , 2013, Journal of thoracic disease.

[16]  Ioanna Kougioumtzi,et al.  Malignant pleural mesothelioma: current and future perspectives. , 2013, Journal of thoracic disease.

[17]  A. Casalini,et al.  YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. , 2013, Anticancer research.

[18]  V. Torri,et al.  The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. , 2013, Critical reviews in oncology/hematology.

[19]  Valerie A Longo,et al.  An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma. , 2013, Surgery.

[20]  N. Davies,et al.  Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. , 2010, Journal of pharmaceutical sciences.

[21]  F. Sonvico,et al.  Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[22]  D. Lardinois,et al.  Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[23]  V. Rousson,et al.  Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  L. Filippich,et al.  Pharmacokinetics of cefaronide, ceftriaxone and cefoperazone in sheep. , 1985, Journal of veterinary pharmacology and therapeutics.

[25]  P. Colombo,et al.  Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma. , 2018, Journal of thoracic disease.

[26]  B. Seifert,et al.  Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. , 2011, The Journal of thoracic and cardiovascular surgery.